The Liverscreen study reaches important threshold

The Liverscreen Study commenced in January 2020 and along with The Center for Liverresearch seven centers across Europe are participating in the study. Among the purposes of the study is the research of whether the non-invasive method, Fibroscan can be used as a tool to diagnose patients with mild fibrosis much earlier than today. Furthermore, the study aim to research the prevalence of fibrosis in the population. The goal is better prediction of which subgroups in a population are to develop fibrosis and cirrhosis. The study is motivated by the fact that the development of fibrosis and cirrhosis is very subtle. Today three out four patients are diagnosed too late, with very limited treatment available and high mortality consequently.

The recruitment of patients in the Liverscreen Study has been highly afflicted by the covid-19 crisis. Therefore, it is with great pleasure that we can celebrate the halfway mark towards the goal of 30000 recruited participants. The Center for Liverresearch has been blessed with a huge amount of awareness and goodwill to participate from the Danish population. We have contributed with more than 2900 participants exclusively to the Liverscreen Study. We are very grateful an proud of our contribution to the research, which hopefully will make a huge difference in the future for patients with fibrosis and cirrhosis.